Hans-Reinhard Zerkowski
Directeur/Bestuurslid bij Medtentia International Ltd. Oy
Profiel
Hans-Reinhard Zerkowski is currently the Director at Medtentia International Ltd.
Oy.
He previously held positions as the President & Chief Executive Officer at LIFEBRIDGE Medizintechnik AG from 2011 to 2014, Executive Chairman & Managing Director at AEVIS VICTORIA SA from 2010 to 2011, Director at Medtentia AB, Chief Surgeon & Head-Cardio Thoracic Surgery at Martin-Luther-Universität Halle-Wittenberg, Partner at BioMedPartners AG, and Member-Supervisory Board at Clinique Générale Ste-Anne SA. He was also a Member-Management Board at Universitätsspital Basel from 1998 to 2006.
Dr. Zerkowski obtained his doctorate degree from the University of Duisburg-Essen in 1980.
Actieve functies van Hans-Reinhard Zerkowski
Bedrijven | Functie | Begin |
---|---|---|
Medtentia International Ltd. Oy
Medtentia International Ltd. Oy Medical SpecialtiesHealth Technology Medtentia International Ltd. Oy is a holding company that develops solutions for mitral valve repair based on its proprietary helix ring concept. It is a medical technology company that creates solutions for cardiac interventions. It provides proprietary, helix-shaped products to address the unmet need in cardiac surgery. The company was founded by Dan Mogren and Olli U. Keränen in 2002 by Olli Keränen and is headquartered in Espoo, Finland. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Hans-Reinhard Zerkowski
Bedrijven | Functie | Einde |
---|---|---|
AEVIS VICTORIA SA | Voorzitter | 10-02-2011 |
Universitätsspital Basel
Universitätsspital Basel Hospital/Nursing ManagementHealth Services Universitätsspital Basel provides medical services. It offers medical facilities for the welfare, safety and recovery of patients. The company is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 01-01-2006 |
Martin-Luther-Universität Halle-Wittenberg | Corporate Officer/Principal | - |
Clinique Générale Ste-Anne SA | Directeur/Bestuurslid | - |
BioMedPartners AG
BioMedPartners AG Investment ManagersFinance BioMedPartners AG (BMP), is an independant venture capital firm headquartered in Basel, Switzerland. BMP originated in 2002 as Seed Capital Advisors AG. The firm manages sector-focused venture capital funds including BioMedInvest, BioMedInvest II and BioMedCredit. They specialize in the biomedical sector. | Corporate Officer/Principal | 01-02-2000 |
Opleiding van Hans-Reinhard Zerkowski
University of Duisburg-Essen | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
AEVIS VICTORIA SA | Health Services |
Bedrijven in privébezit | 6 |
---|---|
BioMedPartners AG
BioMedPartners AG Investment ManagersFinance BioMedPartners AG (BMP), is an independant venture capital firm headquartered in Basel, Switzerland. BMP originated in 2002 as Seed Capital Advisors AG. The firm manages sector-focused venture capital funds including BioMedInvest, BioMedInvest II and BioMedCredit. They specialize in the biomedical sector. | Finance |
LIFEBRIDGE Medizintechnik AG
LIFEBRIDGE Medizintechnik AG Medical SpecialtiesHealth Technology LIFEBRIDGE Medizintechnik AG develops medical technology and produces & markets life-saving support systems which apply state-of-the-art technologies to extracorporeal circulation. It markets its products under the brand name LIFEBRIDGE B2T. The firm has set itself the goal of providing mechanical cardiovascular support to significantly more patients than are receiving such support today in the decisive moments of their lives. This challenge has been taken up by experienced entrepreneurs, engineers, physicians and investors in order, through their know-how and commitment, to set new technological standards in invasive emergency medicine. Acknowledged experts from the worlds of medicine, science and industry are making their crucial contributions with conviction to close life-threatening gaps in the chain of medical care. | Health Technology |
Clinique Générale Ste-Anne SA | |
Medtentia International Ltd. Oy
Medtentia International Ltd. Oy Medical SpecialtiesHealth Technology Medtentia International Ltd. Oy is a holding company that develops solutions for mitral valve repair based on its proprietary helix ring concept. It is a medical technology company that creates solutions for cardiac interventions. It provides proprietary, helix-shaped products to address the unmet need in cardiac surgery. The company was founded by Dan Mogren and Olli U. Keränen in 2002 by Olli Keränen and is headquartered in Espoo, Finland. | Health Technology |
Universitätsspital Basel
Universitätsspital Basel Hospital/Nursing ManagementHealth Services Universitätsspital Basel provides medical services. It offers medical facilities for the welfare, safety and recovery of patients. The company is headquartered in Basel, Switzerland. | Health Services |
Medtentia AB
Medtentia AB Medical SpecialtiesHealth Technology Novel medical devices for minimal invasive cardiac valve surgery. Medtentia has completed preclinical validation for its first product. Investors Inveni Capital and Industrifonden will take the company through its clinical development phase. Early human trials have been completed successfully Q1 in 2009. Medtentia's technology is patented in USA and patent pending in Europe. Medtentia is a venture-backed medical device company focused on the development of minimally invasive and percutaneous heart valve repair and replacement devices on currently proven therapy. Medtentia will act on a global basis with its core activities and team located to Europe with main office in Helsinki Finland and in the Medicon Valley region of southern Sweden in Lund. Medtentia is currently developing a technology platform of products to enable rapid surgical mitral valve annulus repair and replacement, perform percutaneous mitral repair and replacement, leverage currently accepted therapeutic practice and reduce invasiveness, procedural time and morbidity. | Health Technology |